Trials / Completed
CompletedNCT03663205
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 334 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the efficacy and safety of tislelizumab in combination with platinum (cisplatin or carboplatin) and pemetrexed compared with platinum and pemetrexed alone as first-line treatment in participants with Stage IIIB or IV non-squamous non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | Administered intravenously |
| DRUG | Cisplatin | Administered intravenously |
| DRUG | Carboplatin | Administered intravenously |
| DRUG | Pemetrexed | Administered intravenously |
Timeline
- Start date
- 2018-07-23
- Primary completion
- 2020-01-23
- Completion
- 2023-04-26
- First posted
- 2018-09-10
- Last updated
- 2025-02-04
- Results posted
- 2024-11-25
Locations
47 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03663205. Inclusion in this directory is not an endorsement.